Childhood Arthritis and Rheumatology Research Alliance Biologic Disease-Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis

IF 3.7 2区医学 Q1 RHEUMATOLOGY

Arthritis Care & Research Pub Date : 2024-06-27 DOI:10.1002/acr.25393

Stacey E. Tarvin, Matthew A. Sherman, Hanna Kim, Nayimisha Balmuri, Amanda G. Brown, Albert Chow, Harry L. Gewanter, Marietta M. de Guzman, Adam M. Huber, Susan Kim, Marisa S Klein-Gitelman, Megan M. Perron, Angela Byun Robinson, Sara E. Sabbagh, Sonia Savani, Susan Shenoi, Jacob Spitznagle, Cory Stingl, Grant Syverson, Heather Tory, Charles Spencer, for the Childhood Arthritis and Rheumatology Research Alliance Juvenile Dermatomyositis Workgroup

{"title":"Childhood Arthritis and Rheumatology Research Alliance Biologic Disease-Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis","authors":"Stacey E. Tarvin, Matthew A. Sherman, Hanna Kim, Nayimisha Balmuri, Amanda G. Brown, Albert Chow, Harry L. Gewanter, Marietta M. de Guzman, Adam M. Huber, Susan Kim, Marisa S Klein-Gitelman, Megan M. Perron, Angela Byun Robinson, Sara E. Sabbagh, Sonia Savani, Susan Shenoi, Jacob Spitznagle, Cory Stingl, Grant Syverson, Heather Tory, Charles Spencer, for the Childhood Arthritis and Rheumatology Research Alliance Juvenile Dermatomyositis Workgroup","doi":"10.1002/acr.25393","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>The objective was to develop consensus treatment plans (CTPs) for patients with refractory moderately severe juvenile dermatomyositis (JDM) treated with biologic disease-modifying antirheumatic drugs (bDMARDs).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The Biologics Workgroup of the Childhood Arthritis and Rheumatology Research Alliance JDM Research Committee used case-based surveys, consensus framework, and nominal group technique to produce bDMARD CTPs for patients with refractory moderately severe JDM.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Four bDMARD CTPs were proposed: tumor necrosis factor α (TNFα) inhibitor (adalimumab or infliximab), abatacept, rituximab, and tocilizumab. Each CTP has different options for dosing and/or route. Among 76 respondents, consensus was achieved for the proposed CTPs (93% [67 of 72]) as well as for patient characteristics, assessments, outcome measures, and follow-up. By weighted average, respondents indicated that they would most likely administer rituximab, followed by abatacept, TNFα inhibitor, and tocilizumab.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>CTPs for the administration of bDMARDs in refractory moderately severe JDM were developed using consensus methodology. The implementation of the bDMARD CTPs will lay the groundwork for registry-based prospective comparative effectiveness studies.</p>\n </section>\n </div>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":"76 11","pages":"1532-1539"},"PeriodicalIF":3.7000,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arthritis Care & Research","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/acr.25393","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

The objective was to develop consensus treatment plans (CTPs) for patients with refractory moderately severe juvenile dermatomyositis (JDM) treated with biologic disease-modifying antirheumatic drugs (bDMARDs).

Methods

The Biologics Workgroup of the Childhood Arthritis and Rheumatology Research Alliance JDM Research Committee used case-based surveys, consensus framework, and nominal group technique to produce bDMARD CTPs for patients with refractory moderately severe JDM.

Results

Four bDMARD CTPs were proposed: tumor necrosis factor α (TNFα) inhibitor (adalimumab or infliximab), abatacept, rituximab, and tocilizumab. Each CTP has different options for dosing and/or route. Among 76 respondents, consensus was achieved for the proposed CTPs (93% [67 of 72]) as well as for patient characteristics, assessments, outcome measures, and follow-up. By weighted average, respondents indicated that they would most likely administer rituximab, followed by abatacept, TNFα inhibitor, and tocilizumab.

Conclusion

CTPs for the administration of bDMARDs in refractory moderately severe JDM were developed using consensus methodology. The implementation of the bDMARD CTPs will lay the groundwork for registry-based prospective comparative effectiveness studies.

查看原文本刊更多论文

儿童关节炎和风湿病学研究联盟针对难治性中度严重幼年皮肌炎的生物 DMARD 共识治疗方案。

目标：目的是为接受生物制剂改善病情抗风湿药物（bDMARDs）治疗的难治性中重度幼年皮肌炎（JDM）患者制定共识治疗方案（CTPs）：方法：儿童关节炎和风湿病学研究联盟（CARRA）JDM研究委员会的生物制剂工作组采用病例调查、共识框架和名义小组技术，为难治性中重度幼年皮肌炎患者制定了bDMARD CTP：结果：提出了四种 bDMARD CTP：结果：提出了四种 bDMARD CTP：TNF-α 抑制剂（阿达木单抗或英夫利昔单抗）、阿巴他赛普、利妥昔单抗和托珠单抗。每种 CTP 都有不同的剂量和/或途径选择。在 76 位受访者中，就建议的 CTP（93% [67/72]）以及患者特征、评估、结果测量和随访达成了共识。通过加权平均，受访者表示他们最有可能使用利妥昔单抗，其次是阿巴他赛、TNF-α抑制剂和托珠单抗：结论：针对难治性中重度 JDM 使用 bDMARDs 的 CTP 是采用共识方法制定的。bDMARD CTPs 的实施将为以登记为基础的前瞻性疗效比较研究奠定基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Arthritis Care & Research RHEUMATOLOGY-

CiteScore

9.40

自引率

6.40%

发文量

368

审稿时长

3-6 weeks

期刊介绍： Arthritis Care & Research, an official journal of the American College of Rheumatology and the Association of Rheumatology Health Professionals (a division of the College), is a peer-reviewed publication that publishes original research, review articles, and editorials that promote excellence in the clinical practice of rheumatology. Relevant to the care of individuals with rheumatic diseases, major topics are evidence-based practice studies, clinical problems, practice guidelines, educational, social, and public health issues, health economics, health care policy, and future trends in rheumatology practice.